LONDON--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today new market research which found 79% ...
A population-based cohort study from 250 centres in the Diabetes Prospective Follow-up, including 13,922 people aged 2-20 years with T1D, of whom 7088 used HCL and 6834 open-loop therapy. The median ...
Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for ...
Please provide your email address to receive an email when new articles are posted on . Diabetes technologies have been evolving rapidly in recent years and now serve a wide range of patients. Usage ...
As the number of people with Type 1 and Type 2 diabetes continues to rise, clinicians and scientists are working together to find pragmatic, patient-centered solutions that could also lessen the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results